SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs quarterly results beat expectations and lifted its outlook, with rapid U.S. commercial AI growth overtaking government revenue for the first time. The shares nevertheless fell, as traders debated whether strong growth was already priced in given the companys high valuation, while others viewed the selloff as a disconnect from the results.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples earnings beat estimates, but traders focused on expected margin pressure from rising memory costs and weaker-than-expected China, iPad, and wearables results, driving a selloff despite strong iPhone sales. The community is split between viewing the drop as an overreaction to a solid quarter and seeing the outlook and valuation as reasons for caution.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavaxs Sanofi partnership is the main focus after a milestone was triggered by the start of a Phase 3 COVID-flu combination trial. Bulls view it as validation of the licensing model and a source of future royalties, while skeptics point to modest vaccine sales and question whether the Q3 results will show meaningful recurring revenue.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is drawing attention ahead of the FDAs Nov. 22 decision on deramiocel for Duchenne muscular dystrophy, with traders focusing on the applications upper-limb function data and new commercial-hiring listings as possible signs of launch preparationnot confirmation of approval. Optimism about a limited upper-limb approval and potential short covering competes with concerns about the FDAs earlier advisory-panel vote and the risk of a rejection; some traders also cite INOs recent approval as a positive read-through, while leak claims remain speculation.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstarts sharp selloff and repeated lows have traders focused on concerns about high interest rates, funding and debt, and the outlook for consumer lending ahead of earnings. Some expect further downside if results or guidance disappoint, while bullish traders argue the decline may be overdone and point to growth potential or a possible short squeeze.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned stock-and-bond fundraising for its AI data-center buildout is drawing scrutiny over dilution, debt and the timing of the capital raise, alongside weakness in tech shares. Traders are split between viewing the drop as an overreaction to a previously disclosed plan and worrying that heavy AI spending may not deliver returns quickly enough.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

A report that nonprofit Usona may have submitted an FDA application for psilocybin in major depressive disorder has sparked fears that a competitor could reach the market before COMPASS Pathways COMP360 for treatment-resistant depression, pressuring its pricing and commercial opportunity. Traders debate whether Usonas MDD focus materially threatens COMPASSs TRD program, and some view the selloff as an overreaction; uncertainty over the report and COMPASSs own NDA timeline remains central.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells agreed all-stock acquisition of Lumentum is driving attention, with traders focused on shareholder dilution, the long path to closing, and whether the deals price and execution risks outweigh its AI-optics rationale. The sharp selloff has fueled criticism that Marvell overpaid, while some investors argue the combination could strengthen its position in AI data-center connectivity over the long term.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion centers on the U.S. midterm elections and how a possible shift in congressional control could affect DJT shares, with bearish traders anticipating pressure and bulls arguing the stock could rally. Many also characterize its moves as speculative pump-and-dump trading, while Iran-war and peace-talk headlines appear as a secondary source of market uncertainty.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

Biotechs pullback and relative resilience are the main focus: traders say IBB is holding up better than small-cap XBI, while debating whether recent sector strength and upcoming large-biotech earnings can sustain momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVA

EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVA EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVAPR NewswireNEW YORK, Oct. 3, 2026NEW YORK, Oct. 3, 2026 /PRNewswire/ --Class Action Attorney Juan Monteverde with Monteverde...

Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy

Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in private financing for Phase 2 clinical trials.read more...

Lisata Therapeutics Acquires Marea Therapeutics; Announces Concurrent Private Placement

(RTTNews) - Lisata Therapeutics (LSTA) has acquired Marea Therapeutics, a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop next-generation medicines for cardioendocrine diseases. The acquisition was structured as a stock-for-stock t...

Lisata Therapeutics Seeks $2 Mln Termination Fee Over Merger Dispute With Kuva, Cuts 72% Workforce

(RTTNews) - Tuesday, Lisata Therapeutics, Inc. (LSTA) announced it has filed a lawsuit against Kuva Labs Inc. and its subsidiary, Kuva Acquisition Corp., in the Delaware Court of Chancery over breach of the merger agreement...

Lisata Therapeutics Stock Falls After Hours: Here's Why

Lisata Therapeutics stock fell after hours after updating investors on its pending acquisition and tender offer.read more...

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers

AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million.
Lisata Therapeutics (NASDAQ:LSTA)read more...

Are LSTA, MCHX, CZR Obtaining Fair Deals for their Shareholders?

Are LSTA, MCHX, CZR Obtaining Fair Deals for their Shareholders? Are LSTA, MCHX, CZR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 16, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?

Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 14, 2026 Insiders may stand to...

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Lisata...

Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken private by Kuva Labs for $5.00 per share + $1.00 CVR.read more...

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its product, Certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

Lisata Therapeutics Inc

Lisata Shares Nearly Double On Buyout Offer: Here Are The Details

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Lisata and Kuva intend to enter into a definitive purchase agreement before Feb 27.</li><li>Under the deal, Kuva will commence a tender offer to purchase all of the outstanding shares of common stock of Lisata at a price of $4.00 per share in cash.</li><li>Lisata shareholders will also be entitled to up to $2 per share contingent upon the achievement of certain pre-specified milestones.</li></ul>&nbsp;Shares of Lisata Therapeutics, Inc. (LSTA) soared 88% on Wednesday after the company said that it has a buyout offer from privately held Kuva Labs, Inc., valuing the company at up to $6/share.Lisata <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-enters-term-sheet-be-acquired-kuva-labs-400">said</a> that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement whereby Kuva will commence a tender offer to purchase all of the outstanding shares of common stock of Lisata at a price of $4.00 per share in cash. In addition, Lisata shareholders will be entitled to up to $2 per share contingent upon the achievement of certain pre-specified milestones.The transaction has been approved by the board of both companies and Lisata and Kiuva intend to enter into a definitive purchase agreement before Feb 27, Lisata said.The $4 upfront purchase price represents a premium of about 85% from the stock’s closing price on Tuesday.<h2 class="st-heading-2">Lisata’s Pipeline</h2>Lisata’s lead product candidate Certepetide is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively.In November 2024, Kuva had licensed Certepetide as a targeting and enhanced delivery agent to be used with its NanoMark platform technology. The NanoMark platform enables selective imaging of solid tumors with high contrast and spatial resolution, facilitating faster and more accurate diagnosis and treatment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LSTA stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that they are not selling their shares for below $8.<stembedurl>https://www.stocktwits.com/iNeedMillions/message/642431338</stembedurl>Another wondered if some other company would make a higher bid for Lisata.<stembedurl>https://www.stocktwits.com/Defen/message/642409160</stembedurl><a href="https://stocktwits.com/symbol/LSTA">LSTA stock</a> has gained 4% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-dismisses-rumors-of-1700-layoffs-at-german-gigafactory-report/cmUDDUFR4fV">Tesla Dismisses Rumors Of 1700 Layoffs At German Gigafactory: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$1.01
Prev Close	$1.02
Open	$1.08
Dividend Yield	0.00%
50-Day Moving Average	$1.38
Beta	0.60
Avg. Volume	106,745.96
PE Ratio	-0.62

52-Week High	$5.07
52-Week Low	$0.9604
Market Capitalization	$11.02M
EPS (Annual)	-$1.91
Price to Book	1.12
Revenue Per Employee	$8,095.24

Feed

News

Sentiment

Earnings

Fundamentals

Info

LSTA Fundamentals